- CFO Spotlights
- Profiles
- Jing-Zhou Chen
Profile
Jing-Zhou Chen
chief executive officer and chief financial officer, Acro Biomedical Co., Ltd.
In the seat. First published here October 28, 2026; built from records as of October 28, 2026.
Jing-Zhou Chen has been chief executive officer and chief financial officer of Acro Biomedical Co., Ltd. since September 2, 2026, according to the company's filing of September 2, 2026.1
The filing gives Jing-Zhou Chen's previous role as Chief Executive Officer and founder at Dream Born Co., Ltd.1 Jing-Zhou Chen joined from outside Acro Biomedical Co., Ltd., by the record's reading of the filing.1
Another profile on this site carries the same name: Jing-Zhou Chen of VitaSpring Biomedical Co. Ltd.. The filings do not establish that they are the same person, so the records are kept apart.
Seats
The seat in the record
| Company | Title as filed | Standing |
|---|---|---|
| Acro Biomedical Co., Ltd. (ACBM) Services-Amusement & Recreation Services | chief executive officer and chief financial officer | In the seat |
Company names link to the company's page in the record at CFO Tribune, which holds the seat history.
The record
Filing by filing, latest first
- September 2, 2026effective
Acro Biomedical Co., Ltd. appointed Jing-Zhou Chen as chief executive officer and chief financial officer, effective September 2, 2026.
On September 2, 2026, the Company's board of directors appointed Jing-Zhou Chen as chief executive officer and chief financial officer, effective on September 2, 2026.
[1] Filing by Acro Biomedical Co., Ltd., filed with the SEC on September 2, 2026. Read the filing. The record at CFO Tribune.
Sources
Sources
- Current report filed with the SEC, Acro Biomedical Co., Ltd.. U.S. Securities and Exchange Commission, EDGAR, filed September 2, 2026. sec.gov; record.
Corrections and removal
If a line here is wrong, or Jing-Zhou Chen wants this profile taken down, write to corrections@cfospotlights.com. Corrections are made on the page with a dated note; removal requests are answered within 72 hours. The underlying filings stay public at the SEC.